ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
EBITDA history
Currency unavailable · from the income statement
No EBITDA data reported for this period type.
EBITDA vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -€42.88M EUR | -67.7% | — | 319.0% | |
| LTM Mar 2026 | -$53.46M USD | -44.4% | — | — | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
| FY2025 | -$76.5M USD | — | — | 410.9% | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$95.72M USD | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$164.11M USD | -405.9% | — | 511.5% | |
| LTM Mar 2026 | -$174.59M USD | -68.4% | — | 243.2% | |
| LTM Mar 2026 | -$190.9M USD | +2.4% | — | 4732.2% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -44.4% | — | 365.0% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.